11 marzo 2021 06:47
Fonte: Adnkronos
#salute-e-benessere
NETANYA, Israel, March 10, 2021 /PRNewswire/ Perflow Medical, a private, Israeli-based innovator of solutions for neurovascular treatment, today announced it has launched to the European market the Cascade™ 17 Non-Occlusive Remodeling Net. Expanding the Cascade product family, the Cascade17 optimizes non-occlusive support of distal and tortuous vessel anatomy during coil embolization of intracranial aneurysms of smaller vessels. The Cascade17 is the latest addition to Perflow s portfolio of neurovascular devices based on a novel proprietary technology platform, the CEREBRAL NET™, which includes the Stream™ Dynamic Neuro-Thrombectomy Net (Stream Net). Early clinical experience with the Cascade17 is extremely promising and further expands the range of brain vessels that can now be treated with Perflow s unique CEREBRAL NET technology. The non-occlusive net design enables continuous blood flow during cerebral aneurysm
(0)
- Published in the
New England Journal of Medicine (NEJM), the REDUCE Study continues to show the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone. ,¹ CARDIOFORM Septal Occluder can be trusted for patient safety and effective defect closure.
FLAGSTAFF, Ariz., March 11, 2021 /PRNewswire/ W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of
The New England Journal of Medicine (NEJM), highlighting the benefits of patent foramen ovale (PFO) closure. The extended follow-up data further supports the use of GORE CARDIOFORM Septal Occluder in long-term recurrent stroke prevention.
Nutra Pharma Corporation: Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials
Plantation, Florida (Newsfile Corp. - March 11, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products; including their technologies for the treatment of Multiple Sclerosis (MS) and potential countermeasures against nerve agents like sarin gas and VX. As part of this process, Nutra Pharma today announ